IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 20,000 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 20,000 shares of the stock in a transaction dated Wednesday, November 12th. The stock was purchased at an average cost of $1.04 per share, for a total transaction of $20,800.00. Following the completion of the purchase, the insider directly owned 783,714 shares of the company’s stock, valued at approximately $815,062.56. The trade was a 2.62% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Stock Performance

NASDAQ IRIX opened at $0.88 on Thursday. The business has a fifty day moving average price of $0.73 and a 200 day moving average price of $0.95. IRIDEX Corporation has a one year low of $0.61 and a one year high of $1.65. The company has a market cap of $15.46 million, a P/E ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. As a group, sell-side analysts predict that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On IRIDEX

Several hedge funds and other institutional investors have recently made changes to their positions in IRIX. United Capital Financial Advisors LLC purchased a new position in IRIDEX during the second quarter worth approximately $41,000. Weber Capital Management LLC ADV acquired a new position in IRIDEX during the second quarter worth $206,616. Diversify Advisory Services LLC acquired a new position in IRIDEX during the second quarter worth $30,000. Bank of New York Mellon Corp purchased a new stake in IRIDEX in the 2nd quarter valued at $29,000. Finally, Renaissance Technologies LLC increased its stake in shares of IRIDEX by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after acquiring an additional 25,067 shares during the last quarter. Institutional investors and hedge funds own 20.10% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.00.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.